Previously, we found that CAPS1 could be used as a serum biomarker for HCC diagnosis by the MB-based MALDI-TOF-MS approach [11], which implied that CAPS1 may have also participated in the tumorigenesis of endodermal tumors. This evidence concerns the gene CAPS and hepatocellular carcinoma.